- Conditions
- Lung Cancer
- Interventions
- carboplatin, etoposide, ifosfamide, topotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Distal Subungual Onychomycosis
- Interventions
- MOB015B, MOB015B Vehicle
- Drug
- Lead sponsor
- Moberg Pharma AB
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Multiple Locations, California • Multiple Locations, Florida • Multiple Locations, Idaho + 6 more
- Conditions
- Schizophrenia
- Interventions
- Lurasidone
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Cerritos, California • Downey, California + 31 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- midostaurin, Bortezomib, mitoxantrone hydrochloride, etoposide, cytarabine
- Drug
- Lead sponsor
- Alison Walker
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Interventions
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Solid Tumor
- Interventions
- FT825, Fludarabine, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2044
- U.S. locations
- 14
- States / cities
- Gilbert, Arizona • La Jolla, California • New Haven, Connecticut + 11 more
- Conditions
- Head and Neck Cancer, Pharynx Cancer
- Interventions
- Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib
- Radiation · Drug
- Lead sponsor
- David M. Brizel, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- dolasetron mesylate, granisetron hydrochloride, ondansetron, prochlorperazine, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Venetoclax
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- Duarte, California • Irvine, California • Aventura, Florida + 16 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- TC-6987, Placebo
- Drug
- Lead sponsor
- Targacept Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 18
- States / cities
- Jonesboro, Arkansas • Mountain Home, Arkansas • Buena Park, California + 15 more
- Conditions
- Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
- Interventions
- Cladribine, Laboratory Biomarker Analysis, Rituximab
- Drug · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pain, Postoperative, Surgical Procedure, Unspecified
- Interventions
- Liposomal Bupivacaine, Bupivacaine HCl
- Drug
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Thoracic Diseases, Urinary Retention
- Interventions
- Tamsulosin Hydrochloride
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
- Interventions
- Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
- Drug · Dietary Supplement
- Lead sponsor
- Washington State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Neoplasms
- Interventions
- Cetuximab + Erlotinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Healthy
- Interventions
- Ritonavir-boosted Atazanavir, Ritonavir-boosted Atazanavir plus Rabeprazole, Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- STAHIST NDC #58407-536-01
- Drug
- Lead sponsor
- Magna Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, cisplatin, paclitaxel, topotecan hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 10
- States / cities
- Fresh Meadows, New York • New York, New York • The Bronx, New York + 2 more
- Conditions
- Acute Myocardial Infarction (AMI)
- Interventions
- Clopidogrel, Prasugrel, Ticagrelor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 377,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anesthesia, Opioid Use
- Interventions
- Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol
- Behavioral · Other · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- LMS - Leiomyosarcoma, Uterine Leiomyosarcoma
- Interventions
- Gemcitabine, Dacarbazine, Cytoreductive Surgery, Functional Assessment of Cancer Therapy (FACT) G questionnaire, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan, Gadolinium
- Drug · Procedure · Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cancer
- Interventions
- anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Thomas Nickolas, MD MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Nephrolithiasis
- Interventions
- Fexofenadine Hcl 180Mg Tab, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York